Modern Research Associates | Dallas, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
Treatment with any of the following agents within 1 week before day 1 pre-enrollment:
Primary purpose
Allocation
Interventional model
Masking
187 participants in 1 patient group
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal